Sanofi scrapped plans to seek approval of amlitelimab in atopic dermatitis, saying the OX40-ligand antibody would not deliver meaningful improvement over standard care. The decision marks an about-face for the program, which had been positioned as a potential successor to Dupixent. Sanofi characterized the move as part of an ongoing pipeline reassessment, signaling a recalibration of investment priorities in immunology as competitors continue to press for differentiation. The setback puts pressure on amlitelimab’s remaining development options and can influence partner and investor expectations around late-stage dermatology expansion timing.